Shares of Kamada Ltd. (NASDAQ:KMDA - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.05 and traded as low as $7.00. Kamada shares last traded at $7.22, with a volume of 41,907 shares trading hands.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Sidoti raised Kamada to a "hold" rating in a report on Thursday, May 8th. Finally, Benchmark reiterated a "buy" rating and issued a $15.00 target price on shares of Kamada in a report on Thursday, May 15th.
Read Our Latest Stock Report on KMDA
Kamada Stock Performance
The business's fifty day moving average price is $7.39 and its two-hundred day moving average price is $7.05. The firm has a market capitalization of $399.98 million, a P/E ratio of 23.98, a PEG ratio of 0.87 and a beta of 0.93.
Kamada (NASDAQ:KMDA - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $44.02 million during the quarter, compared to the consensus estimate of $154.06 million. Kamada had a net margin of 9.60% and a return on equity of 6.31%. Sell-side analysts predict that Kamada Ltd. will post 0.23 earnings per share for the current year.
Institutional Investors Weigh In On Kamada
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC purchased a new stake in shares of Kamada during the second quarter worth about $1,972,000. Huntleigh Advisors Inc. acquired a new position in Kamada during the 1st quarter valued at approximately $863,000. Jane Street Group LLC purchased a new position in shares of Kamada in the first quarter worth $582,000. Goldman Sachs Group Inc. acquired a new stake in shares of Kamada during the first quarter worth $497,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Kamada during the first quarter valued at $206,000. 20.38% of the stock is currently owned by hedge funds and other institutional investors.
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Read More
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access